60
Participants
Start Date
January 23, 2017
Primary Completion Date
June 12, 2018
Study Completion Date
June 12, 2018
Levomilnacipran
treating major depression. A flexible dose regime of levomilnacipran ER 20-120 mg/d mg per day starting at 20 mg/d on Days 1-2, increasing to 40 mg/d on Days 3-7 in week 1, then flexibly dosed between 40 mg/d -120 mg/d during weeks 2 through 8
Quetiapine
Quetiapine will be started at 50 mg/d on Day 1-2, increasing to 150 mg/d on Days 3-7 in Week 1 and then flexibly dosed between 150-300 mg/d during Weeks 1 through 8 along with their current antidepressant.
Institute for Advanced Medical Research, Alpharetta
Lead Sponsor
Collaborators (1)
Forest Laboratories
INDUSTRY
Institute for Advanced Medical Research, Alpharetta, GA
OTHER
Duke University
OTHER